2Seventy Bio

2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

2Seventy Bio reports solid Q2 revenue, navigates competitive challenges

2Seventy Bio's Q2 2023 performance reflects strong revenue driven by ABECMA, with a focus on innovation and patient care. The company faces challenges from competitive dynamics and FDA clinical holds but is strategically positioned to capitalize on opportunities in the oncology space.

2Seventy Bio addresses challenges, highlights ABECMA support at Q3 call

2Seventy Bio navigated a challenging quarter with a focus on ABECMA support and organizational reshaping.
Key presentations at ASH showcased positive outcomes for ABECMA, while concerns around growth and profitability were addressed.
Management's commitment to stakeholders and strategic partnerships position the company for future growth and success.

2Seventy Bio reports robust Q4 earnings, eyes growth opportunities

2Seventy Bio's Q4 2023 earnings call highlighted strong financial performance, cost-saving initiatives, and confidence in Abecma's market potential.
While facing competition challenges and operational considerations, the company remains focused on growth, innovation, and financial sustainability.
Strategic partnerships, upcoming regulatory milestones, and a clear roadmap to breakeven underscore 2Seventy Bio's commitment to long-term success.

2Seventy Bio focuses on Abecma growth post realignment

2Seventy Bio's Q1 2024 performance was solid, with Abecma revenues meeting expectations.
The company's strategic realignment towards Abecma aims for cost efficiency and growth.
Challenges lie in achieving breakeven by 2025 and sustaining Abecma's market position.
Opportunities exist for increased profitability, market expansion, and operational efficiency.

2Seventy Bio focuses on ABECMA, reports strong Q2 earnings

2Seventy Bio's Q2 performance reflects a strategic shift towards profitability and sustainable growth.
The company's strong financial results and cost-saving measures position it well for future success.
While challenges exist, opportunities in product focus and financial management pave the way for a promising future.
Overall, 2Seventy Bio's focus on ABECMA and profitability sets a positive trajectory for the company.

2Seventy Bio reports robust Q3 growth driven by ABECMA success

2Seventy Bio's Q3 2024 performance reflects a strong return to growth, driven by a focus on ABECMA and operational efficiency.
While challenges such as market dynamics and cost optimization persist, the company's strategic strengths and growth opportunities position it well for the future.
With a positive market response to ABECMA and a commitment to expansion, 2Seventy Bio is poised to capitalize on its strengths and navigate challenges effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management team will also be presenting at the following upcoming investor conferences: TD Cowen 44th Annual Healthcare Conference in Boston, MA on Wednesday, March 6, 2024 at 2:10 p.m. ET Leerink Partners Global Biopharma Conference in Miami, FL on Wednesda.

2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences

2seventy bio, Inc. (TSVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?

2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.

2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up

Regeneron Pharmaceuticals

Cancer treatment maker 2seventy bio will sell all its experimental cell therapies to Regeneron Pharmaceuticals for an upfront payment of $5 million and focus on its sole approved product Abecma, the two companies said on Tuesday.

2seventy bio to sell experimental cell therapies to Regeneron

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T therapy for multiple myeloma. The actions announced today follow an extensive evaluation of the Company's business and strategic alternatives by its Board of Directors. As a result of this strategic re-alignment, the Company expects annual savings of appr.

2seventy bio Announces New Strategic Path Forward

2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About 2seventy bio, Inc. (TSVT) Rating Upgrade to Strong Buy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego. Participants can access the conference call live via webcast which will be available on the Investors.

2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)

Aclaris Therapeutics

Checkpoint Therapeutics

G1 Therapeutics

Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.

Best Penny Stocks To Buy? 4 To Watch With Big News This Week

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value: As we indicated last month, the Board has commenced a process to consider all options to maximize value. This process is well underway and our team is committed to working as thoughtfully and quickly as possible to ensure our important therapies become.

2seventy bio Reiterates Commitment to Maximizing Shareholder Value

Activist investor Engine Capital on Wednesday sent a letter to the board of cancer therapy developer 2seventy bio , urging a board refresh and the appointment of its chief operating officer Chip Baird as CEO, among other changes.

Engine Capital pushes for changes at cancer therapy developer 2seventy bio

NEW YORK--(BUSINESS WIRE)--Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (Nasdaq: TSVT) (“2seventy” or the “Company”) outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the “Board”). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, “Engine” or “we”), is a meaningful shareholder of 2seventy.

Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value

Bristol-Myers

Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for their blood cancer treatment, Abecma, next month as originally planned.

Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug

Shares of Bristol Myers Squibb Co. BMY and 2seventy bio Inc. TSVT fell premarket on Monday after the companies said the U.S. Food and Drug Administration would miss its target date for potential approval of earlier use of a cancer therapy.

Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment

The U.S. Food and Drug Administration (FDA) will not make a decision on Bristol Myers Squibb and 2seventy bio's marketing application of their blood cancer therapy, Abecma, for earlier lines of treatment by Dec. 16.

US FDA delays decision on Bristol Myers-2seventy bio cancer therapy

2seventy bio, Inc. (TSVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

2seventy bio, Inc. (TSVT) Loses -44.63% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Arcutis Biotherapeutics

CRISPR Therapeutics

Some of the most exciting opportunities can be found in biotech stocks. In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money.

3 Biotech Stocks With Key Catalysts Coming in December

2seventy bio, Inc. (NASDAQ:TSVT ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Elizabeth Hickin - Head of IR Nick Leschly - President and CEO Chip Baird - COO Steve Bernstein - Chief Medical Officer Conference Call Participants Yaron Werber - TD Cowen Kelsey Goodwin - Guggenheim Securities Daina Graybosch - Leerink Partners Samantha Semenkow - Citi John Newman - Canaccord Genuity Operator Good day, and thank you for standing by. Welcome to the 2seventy bio Third Quarter 2023 Earnings Conference Call.

2seventy bio, Inc. (TSVT) Q3 2023 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com.

2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023

2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?

NanoString Technologies

In stock trading, shorting is seen as a high-risk, high-reward strategy. This approach involves borrowing stocks, selling them, and betting on their price dropping to make a profit.

Short squeeze alert for October 18th: 2 stocks that could soar

Alnylam Pharmaceuticals

Upcoming announcements from the U.S. Food and Drug Administration could cause several biotech stocks to rocket higher. Alnylam is expecting a decision regarding a progressive heart condition that could lead to billions in additional annual sales.

2 Growth Stocks That Could Rocket Higher Before the End of 2023

2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.

2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal

2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma.

2seventy bio to lay off 40% of workforce

2seventy bio Inc. stock TSVT, -6.81% rose 2.7% in premarket trading on Tuesday after the T-cell drug company for cancer treatment said it's cutting 176 jobs or 40% of its work force and launching a search for a new chief executive. Current chief executive Nick Leschly will become chairman of the company's board.

2seventy bio cutting 176 jobs, search for new chief executive

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a restructuring of its business operations and research and development model to significantly reduce costs while supporting the execution of a prioritized plan for the long-term growth of the company. “2seventy's mission remains the same: to unleash the power of the T-cell and develop un-incremental treatments for people living with cancer,” said Nick Leschly, chief kairos officer. “However, the macro environ.

News for 2Seventy Bio Stock (TSVT)